Skip to main content

Table 5 Chemotherapy outcome prediction using prognostic signatures

From: Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value

Response prediction (n = sample size)

BRmet50

PMID18271932Sig33

pCR

RCB

pCR/RD(n = 993)*

    

Mean PPV(SD)

88(6)

88(5)

NA

NA

Mean NPV(SD)

35(4)

35(6)

NA

NA

RCB(n = 417)**

    

Mean PPV(SD)

85(1)

86(3)

NA

NA

Mean NPV(SD)

42(1)

41(0.3)

NA

NA

DRFS(n = 508)**

    

Mean PPV(SD)

32(0.3)

31(2)

26(0.4)

49(2)

Mean NPV(SD)

88(6)

87(4)

92(0.8)

83(4)

  1. *Five data sets with neoadjuvant chemotherapy records include GSE25055 (anthracycline-taxane ), GSE25065 (anthracycline-taxane ), GDS4057(5-fluorouracil, doxorubicin, and cyclophosphamide), GSE32646 (5-fluorouracil-epirubicin, and cyclophosphamide), GSE41998 (doxorubicin and cyclophosphamide followed by ixabepilone or paclitaxel).
  2. **DRFS: Distant relapse free-survival, 508 samples from two data sets including GSE25055 and GSE25065.